Targets › TRPM7
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 2; Other; next expected readout Dec 2026.
Bifunctional protein that combines an ion channel with an intrinsic kinase domain, enabling it to modulate cellular functions either by conducting ions through the pore or by phosphorylating downstream proteins via its kinase domain. The channel is highly permeable to divalent cations, specifically calcium (Ca2+), magnesium (Mg2+) and zinc (Zn2+) and mediates their influx. (UniProt, Q96QT4)
Open in Phaseline: the race on TRPM7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of California, Davis | Magnesium Sulfate N-methyl-D-aspartate (NMDA) receptor antagonist; modulates ion channels involved in pain s | TRPM7 | Phase 4 | Trauma | Dec 2026 |
| Tanta University | Magnesium sulfate NMDA receptor antagonist and ion channel modulator; enhances local anesthetic effect | TRPM7 | Phase 2 | Pain Score Reduction | – |
Trauma (1) Pain Score Reduction (1)
small molecule (2)
University of California, Davis (1) Tanta University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.